Superworth

XBiotech revenue XBIT

Sales by quarter and over the last twelve months, from 2019.

Last 12 months, to Dec 31, 2023
$0
Latest quarter, Q4 FY23
$0
−100% on a year earlier
Fiscal year 2023
$0
−100% on the year before

XBiotech's revenue was $0 over the twelve months to Dec 31, 2023, down 100% on a year earlier.

In its latest quarter, Q4 FY23, it was $0, down 100% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2023$0−100%
FY2022$4M−78%
FY2021$18.4M−58%
FY2020$44Mn/a
FY2019$0n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q4 FY23$0−100%$0
Q3 FY23$0−100%$300K
Q2 FY23$0−100%$2M
Q1 FY23$0−100%$3.5M
Q4 FY22$300K−93%$4M
Q3 FY22$1.7M−63%$8.2M
Q2 FY22$1.5M−66%$11M
Q1 FY22$500K−90%$14M
Q4 FY21$4.5M−15%$18.4M
Q3 FY21$4.5M−57%$19.2M
Q2 FY21$4.5M−71%$25.2M
Q1 FY21$4.8M−62%$36.2M

Against its peers

Companies in Drug Manufacturers - General nearest XBiotech's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
XBITXBiotechn/m
SPROSpero Therapeutics$47M−3% a year
ATNMActinium Pharmaceuticalsn/m
LFVNLifevantage$182.6M−20% a year
NATRNatures Sunshine Products$492M+7% a year
ARVNArvinas$316.7M−15% a year
PBYIPuma Biotechnology$231.2M−3% a year
IRWDIronwood Pharmaceuticals$389.3M+26% a year
ZVRAZevra Therapeutics$136.1M+119% a year
Peer median$231.2M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on XBiotech

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.